Medicinal Products

Deksametazon Accord 4 mg/ml otopina za injekciju/infuziju

Name Deksametazon Accord 4 mg/ml otopina za injekciju/infuziju
Marketing Authorisation Number HR-H-372263694
Active Substance natrijev deksametazonfosfat
Composition 1 ml otopine sadrži 4 mg deksametazonfosfata (u obliku natrijevog deksametazonfosfata)
Pharmaceutical Form Otopina za injekciju / infuziju
Manufacturer Pharmadox Healthcare Limited, Paola, Malta
Laboratori Fundacio Dau, Barcelona, Španjolska
Accord Healthcare Polska Sp. z o.o., Pabianice, Poljska
Marketing Authorisation Holder Accord Healthcare Polska Sp. z o.o., Ul. Tasmowa 7, Mazowieckie, Varšava, Poljska
Marketing Authorisation Date 20.06.2024
MA Period of Validity 20.06.2029
MA Revocation Date 18.03.2025*
Classification Number UP/I-530-09/22-01/59
Registration Number 381-12-01/70-24-09
Prescription Medicinal product subject to medical prescription
Type of prescription ograničeni recept
Distribution Supply through pharmacies (community)
Advertising to general public not allowed
ATC Code H02AB02
Marketing status nije stavljeno u promet
SmPC download
PL download
Public Assessment Report download
Summary of risk management plan download

*Note

Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.

Packaging

Back